Physician profile
Danae Walker
NPI 1619659968
$2,662.72
in general payments reported to CMS, 2019-2025
28 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $184 · 2024: $1,349 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.72 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.30 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $362.70 | 2023-2024 | Myrisk, Precisetumor |
| Otsuka America Pharmaceutical, INC. | $317.92 | 2023-2025 | Rexulti |
| Amgen INC. | $211.00 | 2024-2025 | Evenity, Repatha, Otezla |
| Lundbeck LLC | $148.60 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $146.27 | 2024-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $104.16 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $103.66 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $103.57 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $84.73 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.36 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $80.63 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $56.58 | 2024 | Dupixent |
| Ironshore Pharmaceuticals INC. | $53.33 | 2023-2024 | Jornay Pm |
| Corium, LLC | $50.02 | 2024 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $46.97 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $44.53 | 2024 | Yupelri |
| Aimmune Therapeutics, INC. | $41.03 | 2025 | Vowst, Zenpep |
| Boston Scientific Corporation | $31.18 | 2024-2025 | Watchman Access System |
| Axsome Therapeutics, INC. | $29.82 | 2025 | Symbravo, Sunosi |
| Viatris Specialty LLC | $20.80 | 2025 | Yupelri |
| Dexcom, INC. | $19.80 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.77 | 2024 | Trelegy Ellipta |
| Sanofi Pasteur INC. | $17.98 | 2025 | |
| Corcept Therapeutics | $17.51 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $17.21 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $15.22 | 2023 | Xarelto |
| Shield Therapeutics INC | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danae Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.